<DOC>
	<DOCNO>NCT00003196</DOCNO>
	<brief_summary>This pilot clinical trial study low-dose total body irradiation donor peripheral blood stem cell transplant follow donor lymphocyte infusion treatment patient non-Hodgkin lymphoma , chronic lymphocytic leukemia , multiple myeloma . Giving total-body irradiation donor peripheral blood stem cell transplant help stop growth cell bone marrow , include normal blood-forming cell ( stem cell ) cancer cell . When healthy stem cell donor infused patient may help patient 's bone marrow make stem cell , red blood cell , white blood cell , platelet . Once donated stem cell begin work , patient 's immune system may see remain cancer cell belong patient 's body destroy . Giving infusion donor 's white blood cell ( donor lymphocyte infusion ) may boost effect .</brief_summary>
	<brief_title>Low-Dose Total Body Irradiation Donor Peripheral Blood Stem Cell Transplant Followed Donor Lymphocyte Infusion Treating Patients With Non-Hodgkin Lymphoma , Chronic Lymphocytic Leukemia , Multiple Myeloma</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine whether mixed hematopoietic chimerism safely establish use non-myeloablative conditioning regimen patient non-Hodgkin lymphoma ( NHL ) , chronic lymphocytic leukemia ( CLL ) multiple myeloma . II . To determine whether mixed chimerism , establish non- myeloablative conditioning regimen , safely convert full donor hematopoietic chimerism infusion donor lymphocyte ( DLI ) . OUTLINE : CYTOREDUCTION : If necessary , patient advance malignancy undergo cytoreductive chemotherapy reduce tumor size discretion primary physician study investigator . CONDITIONING REGIMEN : Patients undergo low-dose total-body irradiation follow allogeneic peripheral blood stem cell ( PBSC ) transplant day 0 . IMMUNOSUPPRESSION : Patients receive cyclosporine intravenously ( IV ) twice daily ( BID ) day -1 0 orally ( PO ) BID day 1-35 taper day 56 . Patients also receive mycophenolate mofetil PO BID day 0-27 . POST-TRANSPLANT DLI : Patients mixed chimerism day 56 evidence graft-vs-host disease ( GVHD ) undergo DLI 30 minute day 65 may receive 3 additional infusion absence GVHD disease progression persistence . Patients achieve mixed chimerism day 56 undergo DLI complete response obtain 2 month monitoring period . After completion study treatment , patient follow 4 , 6 , 12 , 18 , 24 month annually thereafter .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Burkitt Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Large-Cell , Immunoblastic</mesh_term>
	<mesh_term>Plasmablastic Lymphoma</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Lymphoma , B-Cell , Marginal Zone</mesh_term>
	<mesh_term>Mycoses</mesh_term>
	<mesh_term>Mycosis Fungoides</mesh_term>
	<mesh_term>Sezary Syndrome</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Cutaneous</mesh_term>
	<mesh_term>Leukemia , T-Cell</mesh_term>
	<mesh_term>Leukemia-Lymphoma , Adult T-Cell</mesh_term>
	<mesh_term>Leukemia , Hairy Cell</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Peripheral</mesh_term>
	<mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
	<mesh_term>Lymphoma , Large-Cell , Anaplastic</mesh_term>
	<mesh_term>Immunoblastic Lymphadenopathy</mesh_term>
	<mesh_term>Lymphoma , Extranodal NK-T-Cell</mesh_term>
	<mesh_term>Lymphomatoid Granulomatosis</mesh_term>
	<mesh_term>Intraocular Lymphoma</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<criteria>Patients age &gt; 49 year &lt; 66 year NHL , CLL multiple myeloma eligible autologous transplantation fail prior autologous transplantation ; patient NHL CLL must fail prior therapy alkylating agent and/or fludarabine ; patient multiple myeloma must stage II III disease receive prior chemotherapy Patients &lt; 50 year age NHL , CLL multiple myeloma high risk regimen relate toxicity prior autologous transplant preexist chronic disease affect kidney , liver , lung , heart consider case case basis present professional clinical counselor ( PCC ) Patients &lt; 66 year age diseases treatable allogeneic bone marrow transplant ( BMT ) preexist chronic disease affect kidney , liver , lung , heart consider high risk regimen relate toxicity use standard high dose regimen ; autografting must also contraindicated patient must approve protocol PCC principal investigator ; follow disease likely candidate less common disease may consider approve PCC : Myelodysplastic syndrome Myeloproliferative syndrome Acute leukemia remission Chronic myelogenous leukemia ( CML ) 2nd chronic phase Hodgkin 's disease Selected patient diagnosis ( ) old 65 year &lt; 75 year Karnofsky score &gt; = 70 , apart age , fulfill eligibility criterion , ( b ) &lt; 66 year ineligible solely renal dysfunction ; patient must approve transplant PCC principal investigator DONOR : Human leukocyte antigen ( HLA ) genotypically identical sibling DONOR : Donor must consent filgrastim ( GCSF ) administration leukapheresis DONOR : Donor must adequate vein leukapheresis agree placement central venous catheter ( femoral , subclavian ) DONOR : Age &lt; 75 Eligible autologous transplantation Patients rapidly progressive high grade NHL History central nervous system ( CNS ) involvement disease Fertile men woman unwilling use contraceptive technique 12 month follow treatment Females pregnant Patients creatinine clearance &lt; 50 ml/min Cardiac ejection fraction &lt; 40 % cardiac failure require therapy Severe defect pulmonary function test ( defect currently categorize mild , moderate severe ) define pulmonary consultant , receive supplementary continuous oxygen Total bilirubin &gt; 2 x upper limit normal Serum glutamate pyruvate transaminase ( SGPT ) serum glutamic oxaloacetic transaminase ( SGOT ) 4 x upper limit normal Karnofsky score &lt; 50 Patients poorly control hypertension DONOR : Identical twin DONOR : Age le 12 year DONOR : Pregnancy DONOR : Infection human immunodeficiency virus ( HIV ) DONOR : Inability achieve adequate venous access DONOR : Known allergy GCSF DONOR : Current serious systemic illness DONOR : Failure meet Fred Hutchinson Cancer Research Center ( FHCRC ) criterion donation describe Standard Practice Guidelines</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>